Show Summary Details
Page of

Relevance of trial-based economic analyses 

Relevance of trial-based economic analyses
Relevance of trial-based economic analyses

Dr. Henry A. Glick

, Dr. Jalpa A. Doshi

, Dr. Seema S. Sonnad

, and Dr. Daniel Polsky

Page of

PRINTED FROM OXFORD MEDICINE ONLINE ( © Oxford University Press, 2021. All Rights Reserved. Under the terms of the licence agreement, an individual user may print out a PDF of a single chapter of a title in Oxford Medicine Online for personal use (for details see Privacy Policy and Legal Notice).

date: 26 February 2021

This chapter describes nine approaches to designing economic evaluations in clinical trials that will make the results of these studies more relevant to the policy debate about whether a safe and effective therapy provides sufficient value for its cost to justify its use. These include adoption of a cost-effective comparator, adoption of a final outcome such as QALYs, enrolment of a representative sample of the patient population who will use the therapy, adoption of a sufficiently long period of follow-up, enrolment of a sufficient number of participants to adequately power the trial, collection of data on a sufficiently broad set of medical services, not overly prescribing medical care, collection of data to assess/improve transferability, and observation of a sufficiently large or small treatment benefit. It also discusses whether there is a role for these evaluations that exceeds providing inputs to decision models, and the roles played by trial-based and model-based economic evidence.

Access to the complete content on Oxford Medicine Online requires a subscription or purchase. Public users are able to search the site and view the abstracts for each book and chapter without a subscription.

Please subscribe or login to access full text content.

If you have purchased a print title that contains an access token, please see the token for information about how to register your code.

For questions on access or troubleshooting, please check our FAQs, and if you can't find the answer there, please contact us.